Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020.

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

Deal Size: $12.2 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 21, 2020

Details:

The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.